← Human Trials & Peer-Reviewed Studies
Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease.
Plain-language guide to PMID 38651491 (2024): review of Parathyroid Hormone (PTH 1-84).
Key Facts
- PMID
- 38651491
- Journal
- Current opinion in nephrology and hypertension
- Year
- 2024
- Study type
- Review
- Authors
- Evenepoel P et al. (2 authors)
- DOI
- 10.1097/MNH.0000000000000992
What This Paper Covers, in Plain Language
What It Covers
Researchers studied Parathyroid Hormone (PTH 1-84) in this review publication.
Defining the optimal parathyroid hormone (PTH) target in chronic kidney disease (CKD) is challenging, especially for bone outcomes, due to the substantial variability in the skeleton's response to PTH.
Although PTH hyporesponsiveness is as integral a component of CKD-mineral bone disorder as elevated PTH levels, clinical awareness of this condition is limited.
In this review, the researchers will discuss factors and mechanisms contributing to PTH hyporesponsiveness in CKD.
Why It Was Studied
Skeletal PTH hyporesponsiveness in CKD has a multifactorial origin, shows important interindividual variability, and is challenging to estimate in clinical practice.
The variability in skeletal responsiveness compromises PTH as a biomarker of bone turnover, especially when considering populations that are heterogeneous in ethnicity, demography, kidney function, primary kidney disease and mineral metabolism control, and in patients treated with bone targeting drugs.
What Was Measured
The variability in skeletal responsiveness compromises PTH as a biomarker of bone turnover, especially when considering populations that are heterogeneous in ethnicity, demography, kidney function, primary kidney disease and mineral metabolism control, and in patients treated with bone targeting drugs.
Topics PubMed links to this paper include Parathyroid Hormone, Renal Insufficiency, Chronic, Hyperparathyroidism, Secondary, Bone Remodeling, Bone and Bones and Chronic Kidney Disease-Mineral and Bone Disorder.
What This Means in Plain Language
This is a review of Parathyroid Hormone (PTH 1-84).
Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (Current opinion in nephrology and hypertension), a journal based in England.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.